Dexcom Beats Q3, Lifts 2025 Sales Outlook on CGM Momentum

The stock fell after-hours following a guidance lift paired with a lower gross margin outlook.

Overview

Revenue reached $1.21 billion versus $1.18 billion expected, with adjusted earnings of $0.61 per share topping the $0.57 consensus.
Full-year revenue guidance rose to $4.63 billion to $4.65 billion, and the company cut its non-GAAP gross margin outlook to 61% from 62%.
Shares dropped more than 8% after the close to $62.69 despite the top- and bottom-line beat.
Adoption was fueled by broader G7 access including Ontario Drug Benefit coverage and the launch of an AI-powered meal logging feature across G7 and Stelo, with Stelo’s first-year sales surpassing $100 million.
Dexcom submitted its Smart Basal insulin-titration module to the FDA, operates under interim CEO Jake Leach, and continues to face a class action tied to G7.